Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TOP2A | P11388 | 2/20 | 0.61 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202670 | 0.98 | NISCH (0.69) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL5476725 | 0.89 | NISCH (0.79) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL31249900 | 0.88 | NISCH (0.68) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL771337 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1685409 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1882160 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL2518908 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL17826831 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL8141372 | 0.79 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL523059 | 0.79 | LMNA (0.96) | NISCHLMNARECQLTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071459-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11358954-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358954-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3442948-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE INC (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3442948-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE INC (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200347037-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347037-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3442948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Mitobridge, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| CN-109071459-A | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | 米托布里奇公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017180818-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-2542632-A1 | ACTIVE RAY CURABLE INK COMPOSITION, ACTIVE RAY CURABLE INKJET INK COMPOSITION AND PRINTING METHOD USING THE SAME | Ricoh Company, Ltd. (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005849-A1 | ACTIVE RAY CURABLE INK COMPOSITION, ACTIVE RAY CURABLE INKJET INK COMPOSITION AND PRINTING METHOD USING THE SAME | RICOH COMPANY, LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| US-8330039-B2 | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| CN-102782060-A | Active ray curable ink composition, active ray curable inkjet ink composition and printing method using the same | RICOH CO LTD | 2012-11-14 | — | — | CN | disclosed |
| CN-102292826-A | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011108757-A1 | ACTIVE RAY CURABLE INK COMPOSITION, ACTIVE RAY CURABLE INKJET INK COMPOSITION AND PRINTING METHOD USING THE SAME | RICOH COMPANY, LTD. (JP) | 2011-09-09 | — | — | WO | disclosed |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-2242746-A1 | HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-10-27 | — | — | EP | disclosed |
| US-20100180947-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2009098000-A1 | HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347037-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | NISCH 4175/4885LMNA 607/4885RECQL 2059/4885 |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | GIPR, DDC, PGC | NISCH 854/4885LMNA 1103/4885RECQL 161/4885 |
| US-11358954-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | NISCH 4175/4885LMNA 607/4885RECQL 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.